Cannabis and Multiple Sclerosis Spasticity
What the evidence actually says about using cannabis-based medicines to treat muscle stiffness and spasms in MS.
This is one of the strongest medical use cases for cannabis-based medicine — but 'strong' here means modest. Multiple high-quality trials show cannabinoids reduce patient-reported MS spasticity, which is why nabiximols (Sativex) is approved in many countries. Objective spasticity scores barely budge. Effects are real but moderate, work best as add-on therapy, and come with real side effects. The marketing pitch ('cannabis cures MS') is nonsense. The clinical reality ('some patients get meaningful symptom relief') is well-supported.
Not medical advice
This article is educational, not medical advice. Multiple sclerosis is a serious neurological disease. Decisions about treatment — including whether to try cannabis-based medicines, which product, what dose, and how it interacts with your other MS drugs — must be made with a neurologist or MS specialist. Cannabis can interact with immunomodulators, affect cognition (already a concern in MS), and worsen balance and falls. Do not substitute cannabis for disease-modifying therapy.
Plain-language summary
Spasticity — involuntary muscle stiffness and spasms — affects roughly 60–80% of people with MS and is often poorly controlled by first-line drugs like baclofen and tizanidine [1].
Cannabis-based medicines, especially nabiximols (brand name Sativex, a 1:1 THC:CBD oromucosal spray), have been tested in large randomized trials as add-on therapy. The pattern across studies is consistent: about 30–40% of patients report a clinically meaningful (≥30%) reduction in spasticity on a 0–10 self-rated scale Strong evidence [2][3]. Spasm frequency and sleep also improve modestly.
Objective clinician-measured spasticity (the Ashworth scale) shows little to no change Disputed [4]. This gap between 'feels better' and 'measures better' is real and matters for interpretation. Most experts treat it as genuine symptom relief that objective scales fail to capture, rather than placebo.
What probably works
Nabiximols (Sativex) as add-on therapy for resistant spasticity. This is the best-evidenced cannabis use case in neurology. Pooled analyses of randomized controlled trials show roughly a 1-point reduction on the 0–10 patient-rated spasticity numerical rating scale versus placebo, with responder rates around 30–40% among patients who didn't respond adequately to standard antispastics Strong evidence [2][3][5].
The American Academy of Neurology's systematic review concluded oral cannabis extract and nabiximols are 'probably effective' for reducing patient-reported spasticity and pain in MS, with a Level B recommendation Strong evidence [6].
Spasm frequency also drops modestly in trials Strong evidence [3].
Sleep quality improves, partly as a knock-on effect of reduced nocturnal spasms Strong evidence [3].
What might work
MS-related central pain. Several trials and the AAN review suggest moderate benefit for neuropathic pain in MS Weak / limited [6][7].
Bladder overactivity. Some evidence of reduced urinary urgency and incontinence episodes with nabiximols, but trials are smaller and results inconsistent Weak / limited [6][8].
Inhaled or smoked cannabis. A small crossover trial showed reductions in patient-rated spasticity and pain but also significant cognitive impairment Weak / limited [9]. Real-world use is widespread, but high-quality data on smoked flower specifically are limited.
Oral THC (dronabinol) and oral cannabis extract. The large CAMS trial found no improvement on the Ashworth scale but did find patient-reported benefit Disputed [4]. Follow-up data hinted at long-term effects but were inconclusive.
What doesn't work — or has no good evidence
Tremor. Trials have not shown meaningful benefit for MS tremor Strong evidence [6].
Disease modification. No credible human evidence that cannabis or any cannabinoid slows MS progression, reduces relapses, or affects lesion load on MRI No data. Animal models of experimental autoimmune encephalomyelitis have shown immunomodulatory effects from cannabinoids, but these have not translated into clinical disease-modifying outcomes No data.
CBD-only products for spasticity. There is no good evidence that isolated CBD (without THC) reduces MS spasticity at typical consumer doses No data. Marketing claims to this effect outrun the data.
'Indica strains for MS.' The indica/sativa distinction does not reliably predict effects No data. See Indica vs Sativa for why this marketing taxonomy is largely folklore.
What we don't know
- Whether different THC:CBD ratios outperform the 1:1 nabiximols formulation.
- Whether long-term (>1 year) use sustains benefit or develops tolerance — open-label extensions suggest durability, but they're not blinded Weak / limited [5].
- Whether inhaled cannabis is non-inferior to oromucosal spray for spasticity at equivalent cannabinoid doses.
- Optimal dosing in patients with significant cognitive impairment, where THC's cognitive side effects are most problematic.
- Whether minor cannabinoids (CBG, THCV) contribute anything; current evidence is preclinical only No data.
- Effects on falls and fracture risk in ambulatory MS patients, who are already at elevated risk.
Comparison with standard treatments
First-line antispastics in MS are baclofen (oral or intrathecal), tizanidine, gabapentin, and benzodiazepines. All have meaningful evidence and all have side effects — sedation, weakness, dry mouth, hepatotoxicity (tizanidine), dependence (benzodiazepines) [1].
Nabiximols is positioned as add-on therapy when first-line agents fail or are not tolerated, not as a replacement [10]. Head-to-head trials against baclofen or tizanidine are lacking. In responder-enriched trials, patients who don't get meaningful benefit in the first 4 weeks are unlikely to benefit later, which has been built into prescribing guidance [5][10].
Botulinum toxin for focal spasticity and intrathecal baclofen for severe generalized spasticity remain important options that cannabis-based medicines do not replace.
Risks and side effects
Common adverse effects of nabiximols in MS trials include dizziness, fatigue, nausea, dry mouth, somnolence, and application-site discomfort [2][3]. Discontinuation rates for adverse events run roughly 5–10% higher than placebo.
Specific concerns in MS:
- Cognition. MS itself impairs processing speed and memory in many patients. THC adds to this acutely Strong evidence [9].
- Balance and falls. Dizziness from THC compounds existing gait impairment.
- Mood. Anxiety and low mood are more common in MS; THC can worsen anxiety, especially at higher doses.
- Psychosis risk. Personal or family history of psychotic illness is a contraindication.
- Drug interactions. CBD inhibits several CYP450 enzymes and can raise levels of co-administered drugs; this matters less for most MS DMTs but is relevant for clobazam, warfarin, and tacrolimus [11].
- Driving. THC impairs driving; nabiximols product information advises against driving while titrating.
Sources
- Peer-reviewed Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple Sclerosis Journal. 2004;10(5):589-595.
- Peer-reviewed Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. European Journal of Neurology. 2007;14(3):290-296.
- Peer-reviewed Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology. 2011;18(9):1122-1131.
- Peer-reviewed Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet. 2003;362(9395):1517-1526.
- Peer-reviewed Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Multiple Sclerosis Journal. 2010;16(6):707-714.
- Peer-reviewed Koppel BS, Brust JCM, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563.
- Peer-reviewed Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- Peer-reviewed Kavia RBC, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Multiple Sclerosis Journal. 2010;16(11):1349-1359.
- Peer-reviewed Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143-1150.
- Government National Institute for Health and Care Excellence (NICE). Cannabis-based medicinal products. NICE guideline NG144. 2019 (updated). ↗
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.